Tempus AI Study Shows Pre-Screening Panel Exceeds 80% Sensitivity Across 12 Lung Cancer Biomarkers
Bitget2026/10/19 12:37- Tempus AI announced study results showing its AI-enabled pre-screening panel could help identify advanced non-small cell lung cancer patients needing biomarker testing.
- The analysis covered 60,459 cases across 56,969 patients through a collaboration with Pfizer.
- Results were presented at the European Society for Medical Oncology Congress 2026 in Madrid.
- The panel analyzes routine pathology images to help prioritize diagnostic testing, potentially accelerating treatment decisions while preserving limited tumor tissue.
- The panel remains in development as a tool to guide subsequent testing, not replace established molecular or immunohistochemistry tests.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan maintains "Neutral" rating on Johnson & Johnson (JNJ.US): Strong data from two anti-cancer drugs, but valuation premium limits upside potential
Johnson & Johnson’s new prostate cancer drug and head and neck cancer drug Ervantumab both released positive data at ESMO. JPMorgan stated that the pipeline shows differentiated potential but valuations are relatively high, maintaining a Neutral rating.
AI trading hype fades and product competition intensifies: SK Hynix (SKHY.US) leveraged ETF delisted from US stock market and liquidated just three months after launch
Two U.S. leveraged ETFs linked to SK Hynix (SKHY.US)—the Tradr 2X Long SK Hynix Daily ETF and the Tradr 2X Short SK Hynix Daily ETF—will be liquidated around November 12, approximately three months after their listing on July 28.
Australian Dollar bulls seem hesitant below one-month top before Aussie CPI, FOMC meeting
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
Crypto prices
More
